Skip to content


Skyrizi (risankizumab) is an antibody pharmaceutical. Risankizumab was first approved as Skyrizi on 2019-04-23. It is used to treat psoriasis in the USA. It has been approved in Europe to treat psoriasis. It is known to target interleukin-23 subunit alpha.
Trade Name Skyrizi
Common Name Risankizumab
Indication psoriasis
Drug Class Monoclonal antibodies: humanized, interleukins as target
Get full access now